- Cohort study
- Open Access
Change of dopamine receptor mRNA expression in lymphocyte of schizophrenic patients
© Kwak et al, licensee BioMed Central Ltd. 2001
- Received: 4 February 2001
- Accepted: 5 March 2001
- Published: 5 March 2001
Though the dysfunction of central dopaminergic system has been proposed, the etiology or pathogenesis of schizophrenia is still uncertain partly due to limited accessibility to dopamine receptor. The purpose of this study was to define whether or not the easily accessible dopamine receptors of peripheral lymphocytes can be the peripheral markers of schizophrenia.
44 drug-medicated schizophrenics for more than 3 years, 28 drug-free schizophrenics for more than 3 months, 15 drug-naïve schizophrenic patients, and 31 healthy persons were enrolled. Sequential reverse transcription and quantitative polymerase chain reaction of the mRNA were used to investigate the expression of D3 and D5 dopamine receptors in peripheral lymphocytes. The gene expression of dopamine receptors was compared in each group. After taking antipsychotics in drug-free and drug-naïve patients, the dopamine receptors of peripheral lymphocytes were sequentially studied 2nd week and 8th week after medication.
In drug-free schizophrenics, D3 dopamine receptor mRNA expression of peripheral lymphocytes significantly increased compared to that of controls and drug-medicated schizophrenics, and D5 dopamine receptor mRNA expression increased compared to that of drug-medicated schizophrenics. After taking antipsychotics, mRNA of dopamine receptors peaked at 2nd week, after which it decreases but the level was above baseline one at 8th week. Drug-free and drug-naïve patients were divided into two groups according to dopamine receptor expression before medications, and the group of patients with increased dopamine receptor expression had more severe psychiatric symptoms.
These results reveal that the molecular biologically-determined dopamine receptors of peripheral lymphocytes are reactive, and that increased expression of dopamine receptor in peripheral lymphocyte has possible clinical significance for subgrouping of schizophrenis.
- Dopamine Receptor
- Brief Psychiatric Rate Scale
- Peripheral Lymphocyte
- Extrapyramidal Symptom Rate Scale
Schizophrenia, commonly developed in adolescents and young adults, is one of the most common mental disorders, but the pathophysiology and etiology of schizophrenia is still obscure. Numerous studies on dopamine and schizophrenia have suggested that the change in the dopamine system is related to schizophrenia, but there is little direct evidence for the "dopamine hypothesis in schizophrenia". Recent progress in molecular biology and imaging techniques has enabled new insight for schizophrenia research, but these methods are still limited by their availability and often reveal inconsistent results. The "dopamine hypothesis" is largely based on pharmacological manipulation of the dopamine system, either by mimicking [1,2] or reducing the symptoms of schizophrenia . However changes in the dopamine system are influenced not only by dopamine itself, but also by dopamine receptors. Therefore, to elucidate the exact changes in the dopamine system researches about the relationship between dopamine and dopamine receptors are needed.
In the early 1980s, Le Fur reported the existence of high affinity binding sites for [3H]spiroperidol in lymphocyte of peripheral blood , but there has been long debate as to whether these sites are true dopamine receptors or nonspecific binding sites. Recent progress in molecular biology reveals the existence of mRNA of D3, D4, D5 dopamine receptors in peripheral lymphocytes, thereby suggesting that the binding sites for [3H]spiroperidol in peripheral lymphocytes may be true dopamine receptors [5,6,7]. However, the clinical significance of these findings, and whether or not these receptors reflect central dopamine receptors remains uncertain.
The purposes of this study were to examine if the mRNA of peripheral dopamine receptor is statically or dynamically changed in schizophrenia, and whether or not these receptors have some value as a potential peripheral marker reflecting central one in schizophrenia.
Demographic data of study groups
33.9 ± 9.5
37.3 ± 11.4
35.1 ± 9.1
30.8 ± 7.7
Age of symptom onset*
22.5 ± 6.8
26.7 ± 9.2
28.1 ± 7.8
Duration of illness*
12.7 ± 8.3
7.6 ± 5.2
2.5 ± 3.0
36.1 ± 12.9
41.9 ± 25.4
36.9 ± 18.2
Dose of antipsychotics****
1000.1 ± 130.4
769.6 ± 491.2
614.2 ± 234.7
Duration of no-medication
10.61 ± 7.01
(mean months ± SD)
Before taking antipsychotics, clinical scale and the amount of dopamine receptor mRNA were checked in the group of schizophrenics and the amount of dopamine receptor mRNA was checked in controls. At 2nd week and 8th week after taking antipsychotics, the the amount of dopamine receptor mRNA were re-checked in drug-free and drug-naïve patients.
Quantitation of dopamine receptor mRNA
preparation of blood lymphocyte
extraction of total RNA and reverse transcription
oligonucleotide primer used for PCR amplification
Primer used to amplify the dopamine receptor, beta-actin and their competitive mutants
Statistical determinations were performed by using a statistical program (SPSS version 8.0). Mann-Whitney test, independent T-test, Chi-square test, Pearson correlation, multiple regression analysis. One-way ANOVA test, and repeated measure of ANOVA were chosen.
Test for sensitivity and reproducibility of methodology
Concentrations of D3R randomly sampled in 14 patients were checked twice by the same technique for reproducibility. The results were statistically identical (Cronbach's alpha is 0.92). Therefore, RT-PCR was reliable tool for quantitation of mRNA.
Quantitation of dopamine receptor mRNA among study groups
1) Analysis of factors for quatitation of D3R/βA, D5R/βA
Influence of clinical factors on D3R/βA, D5R/βA mRNA ratio in drug-med patients
2) Comparison of D3R/βA, D5R/βA among study groups before taking antipsychotics
D3R/βA, D5R/βA mRNA ratio between normal and schizophrenic patients (mean ± standard error)
2.10 ± 0.47**
2.09 ± 0.63**
19.45 ± 5.57**
7.75 ± 3.21
p < 0.05
0.37 ± 0.10
0.19 ± 0.05**
0.78 ± 0.21**
0.58 ± 0.16
p < 0.05
The D5R/βA ratio was significantly elevated between drug-free patients and drug-med patients, but there was no statistical difference between drug-free patients and normal controls (Figure 5).
3) The relationship between D3R/βA, D5R/βA and drug free duration in drug-free patients
4) Relationship between amount of D3R/βA and clinical profile
Comparison of clinical profiles according to the level of dopamine receptor mRNA before medication (mean ± SD)
High dopamine R
Normal dopamine R
54.08 ± 34.70
34.47 ± 13.43
1.58 ± 2.78
3.25 ± 7.09
5) Change of dopmaine receptor mRNA after antipsycotics
Sequential studies of off-medication patients after antipsychotic medication (mean ± standard error)
19.45 ± 5.57
26.74 ± 6.41
22.01 ± 6.19
0.78 ± 0.21
1.88 ± 0.90
1.62 ± 0.82
7.75 ± 3.21
19.42 ± 5.17
14.11 ± 7.23
0.58 ± 0.16
1.21 ± 0.51
0.74 ± 0.50
Dopamine and Dopaminergic neurons are localized in certain parts of the central nervous system and involved in the pathophysiology of schizophrenia. However, there is no direct evidence of dysfunction of brain dopaminergic systems in schizophrenic patients because no pathognomic change in the dopaminergic system has been found at autopsy and the direct assessment of brain dopaminergic systems in vivo is almost impossible at present. In addition, abnormal function of the dopamine system results not only from the dopamiergic neuron, but from dopamine receptors and these dopamine receptors can be changed secondly by dopamine. Therefore, the importance of the physiological and pathological roles of dopamine receptors is emerging.
Recent progress in molecular biology has revealed 5 distinct subtypes of dopamine receptors, and their structure and physiological functions have been identified. Owing to this advance, receptors other than D2 dopamine receptors, which is traditionally considered to be important in pathophysiology of schizophrenia, have been issued in relation to schizophrenia [10,11,12]. Among these other dopamine receptors, the D3 dopamine receptor is primarily localized in the limbic area, has a high affinity for antipsychotics, and it has been found to be elevated in postmortem study of schizophrenic patients . As a result, the D3 dopamine receptor is considered to be important in the pathophysiology of schizophrenia. Therefore, the notion that the effect of antipsychotic medication is more closely related to D3 dopamine receptors, while extrapyramidal drug side effects are related to the D2 dopamine receptor, is one of the modified dopamine hypotheses [14,15].
The D5 dopamine receptor, belongs to the Dl dopamine receptor subfamily, has a similar nucleotide sequence to the Dl receptor , and a high affinity for dopamine more than the Dl dopamine receptor . The D5 dopamine receptor, which is sparse in area of the Dl dopamine receptor, is mainly localized in the hippocampus, thalamus, and its physiological role is still uncertain . However, some report suggest that the Dl dopamine receptor may be related in negative symptom [19,20] and the fact that the D5 dopamine receptor in the prefrontal cortex is down-regulated by antipsychotics in animal experiment  may suggest that the D5 dopamine receptor is also related to schizophrenia.
Nigrostriatal and mesolimbic dopaminergic pathways are major dopaminergic systems in the brain. D3 dopamine receptor has a high affinity for dopamine , and is preferentially localized in mesolimbic dopamine system, and it projects to the ventral striatum. This receptor is considered to have a major role in cognition and emotion . Therefore, changes of D3 dopamine receptors mediate the changes in the striato-pallidal-thalamo-cortical limbic loop, and these changes are considered to be involved in the symptoms and pathophysiology of schizophrenia . While the nigrostriatal system and D2 dopamine receptors have a major role in pathophysiology in Parkinson's disease, the mesolimbic system and D3 dopamine receptor may be more involved in the pharmacological responsiveness and pathophysiology of schizophrenia.
A major limitation of the dopamine hypothesis in schizophrenia is that there are no suitable in vivo methods for direct assessment of functional changes of the dopamine system in the brain. Though positron emission tomography (PET) can assess D2 dopamine receptors in striatum , PET has limited usability other than striatum, and limbic area and cortex related to schizophrenia is difficult to assess by PET. To assess the changes in dopamine receptors, an easily accessible peripheral marker is needed, and the dopamine receptor of peripheral lymphocyte may be a possible candidate. However, small quantity of mRNA of dopamine receptors in the peripheral lymphocyte is a major limitation to research assessing clinical significance. Methods to quantitate gene expression are Northern blot, RNase protection assay, in situ hybridization, and RT-PCR. Though Northern blot and RNase protection assay are classical tools, the more sensitive RT-PCR is useful in detecting small quantities. In RT-PCR, as the reaction cycle increases, product is exponentially increased. While this exponential increase causes high sensitivity, if not adequately controlled, the initial amount is not precisely assessed. To solve this problem, PCR is done with a primer for a non-competitive endogenous target (βA) as an internal control (multiplex PCR) or with competitive external strands as an external control. For a more accurate assessment, each βA, D3, D5 was quantitated by the addition of a competitive external strand, then the dopamine receptor/βA ratio was done. Since all dopamine receptors and most other receptors related to the G-protein have a similar structure, designing a sensitive and specific primer is critical in performing quantitative RT-PCR. The D3 dopamine receptor especially has a splicing variant without physiological function . Therefore, a sensitive and specific primer for quantitation of the intact form of D3 dopamine receptors is important.
Considering the changes in dopamine receptors after taking antipsychotics, these receptors may have a physiological role, but the relationship between peripheral and central dopamine receptors is still uncertain. In animal experiment, Shenkman concluded that cholinergic muscarine receptors in peripheral lymphocytes are useful markers for cholinergic muscarine bindings in the brain . Dopamine receptors and cholinergic muscarine receptors are all typical G-protein related receptors, and there was a report that D3 mRNA in lymphocyte is decreased in Parkinson's disease, and that the degree of decrease was correlated with the severity of this disease . Considering all the above findings, dopamine receptors in peripheral lymphocyte can be a peripheral marker of central nervous system dopamine receptors. However, there are various expressions of subtypes of dopamine receptors and these show various responses to antipsychotics according to the anatomic substrate in the central nervous system [13, 28]. D3 dopamine receptors in lymphocytes can reflect particular anatomy in the brain, not merely the whole brain, and considering the previous result from a report on D3 dopamine receptor  and a dense population of D3 receptor in the limbic striatum, limbic striatum may be a plausible corresponding site.
In this study, D3 dopamine receptor mRNA was increased in drug-free patients compared to drug-med patients and controls, while somewhat lower levels of D3 dopamine receptor mRNA were found in chronically medicated patients compared to normal controls before taking antipsychotics. The fact that D3 dopamine receptor mRNA is elevated in medicated schizophrenic patients produced similar findings to the report of Gureivch (1997). But after taking antipsychotics, dopamine receptor mRNA peaked at 2nd week, while at 8th week dopamine receptor mRNA had decreased, though the level was still found to be above normal controls. Though long term follow up was not done, considering that dopamine receptor mRNA decreased in chronically medicated patients, dopamine receptor mRNA might decrease to lower levels than that of the control patients.
The difference between drug-free patients and naïve patients is interesting. While dopamine receptor mRNA in drug-free patients is higher than in normal controls, the level of drug-naïve patients, though it increased, is not a statistically higher one. This may be interpreted in two ways:
First, the residual drug effect of antipsychotics due to a short withdrawal period may influence drug-free patients. We analyzed it by correlation with drug withdrawal periods and dopamine receptor mRNA in drug-free patients. The coefficient value is not statistically significant. It is not exactly known how rapidly D2-like receptors return to normal after neuroleptic treatment, but PET study showed that there is no residual increase of dopamine receptor in striatum within a month period of drug withdrawal . Therefore this assumption may be less possible.
Second, there is the possibility of in-born elevation of lymphocyte dopamine receptors in certain schizophrenic patients and the possibility of subgrouping of schizophrenia. To elucidate this possibility, we analyzed drug-free and drug-naïve patients in two groups according to levels of dopamine receptors and compared these two groups with their clinical character. The patients in the high dopamine receptor group had statistically significant high BPRS compared to that of patients in the normal dopamine receptor group. But there was no difference between the two group in ESRS before taking antipsychotics (Table 5). There has been a long debate about the subgrouping of schizophrenia  and the lack of biological markers for this hypothesis is a major limitation. The peripheral dopamine receptor may be a possible candidate for this hypothesis. But due to the small number of study groups, and the limitations of other confounding factors, somewhat cautious conclusions are needed.
We believe a latter interpretation is more plausible but stricter and more prudent prospective study design is necessary before reaching more convincing conclusions. This study indicated that dopamine receptors in peripheral lymphocytes are elevated in certain populations of schizophrenic patients compared to controls before taking antipsychotics, and dynamically changed after taking antipsychotics. Therefore dopamine receptor in peripheral lymphocyte may be an easily accessible candidate for a biological marker and studying a pharmacodynamic study in a future.
This study reveals that the molecular biologically-determined dopamine receptors of peripheral lymphocytes are reactive after taking antipsychotics, and that increased expression of dopamine receptor in peripheral lymphocyte has possible clinical significance for subgrouping of schizophrenis.
- Janowsky DS, el-Yousel MK, Davis JM, Sekerke HJ: Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch Gen Psychiatry. 1973, 28: 185-191.View ArticlePubMedGoogle Scholar
- Angrist B, Gershon S: Clinical response to several dopamine agonists in schizophrenic and nonschizophrenic subjects. Adv Biochem Psychopharmacol. 1977, 16: 667-680.Google Scholar
- Matthysse S: Antipsychotic drug actions: a clue to the neuropathology of schizophrenia. Federation Proc. 1973, 32: 200-208.Google Scholar
- Le Fur G, Phan T, Uzan A: Identification of stereospecific [3H]spiroperidol binding sites in mammalian lymphocytes. Life Sci. 1980, 26: 1139-1148. 10.1016/0024-3205(80)90653-0.View ArticlePubMedGoogle Scholar
- Takahashi N, Nagai Y, Ueno S, Saeki Y, Yanagihara T: Human peripheral blood lymphocytes expression D5 dopamine receptor gene and transcribe the two pseudogenes. FEES Lett. 1992, 314: 23-25. 10.1016/0014-5793(92)81452-R.View ArticleGoogle Scholar
- Nagai Y, Ueno S, Saeki Y, Soga F, Yanagihara T: Expression of the D3 dopamine receptor gene and a novel variant transcript generated by alternative splicing in human peripheral blood lymphocytes. Biochem Biophys Res Commun. 1993, 194: 368-374. 10.1006/bbrc.1993.1829.View ArticlePubMedGoogle Scholar
- Bondy B, de Jonge S, Pander S, Primbs J, Ackenheil M: Identification of dopamine D4 mRNA in circulating lymphocytes using nested polymerase chain reaction. J Neuroimmunol. 1996, 71: 139-144. 10.1016/S0165-5728(96)00148-8.View ArticlePubMedGoogle Scholar
- Overall J, Gorham D: The brief psychiatric rating scale. Psychol Rep. 1962, 10: 799-812.View ArticleGoogle Scholar
- Chouinard A, Ross-Chouinard G: Extrapyramidal symptom rating scale. Can J Neurol Sci. 1980, 7: 233-Google Scholar
- Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC: Molecular cloning and a characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 1990, 347: 146-151. 10.1038/347146a0.View ArticlePubMedGoogle Scholar
- Crocq MA, Mant R, Asherson P, Williams J, Hode Y, Mayerova A, Collier D, Lannfelt L, Sokoloff P, Schwartz JC, et al: Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. J Med Genet. 1992, 29: 858-860.View ArticlePubMedPubMed CentralGoogle Scholar
- Arinami T, Itokawa M, Enguchi H, Tagaya H, Yano S, Shimizu H, Hamaguchi H, Tom M: Association of dopamine D2 receptor molecular variant with schizophrenia. Lancet. 1994, 343: 703-704. 10.1016/S0140-6736(94)91581-4.View ArticlePubMedGoogle Scholar
- Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE, Joyce JN: Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. Arch Gen Psychiatry. 1997, 54: 225-232.View ArticlePubMedGoogle Scholar
- Meltzer HY: The mechanism of action of novel antipsychotic drugs. Schizophr Bull. 1991, 17: 263-287.View ArticlePubMedGoogle Scholar
- Sigmundson HK: Pharmacotherapy of schizophrenia: a review. Can J Psychiatry. 1994, supple 39: 70-75.Google Scholar
- Sunahara RK, Guan HC, O'Dowd BF, Seeman P, Laurier LG, Ng G, George SR, Torchia J, Van Tol HH, Niznik HB: Cloning of the gene for a human dopamine D5 receptor with high affinity for dopamine than Dl. Nature. 1991, 350: 614-619. 10.1038/350614a0.View ArticlePubMedGoogle Scholar
- Weinshank RL, Adham N, Macchi M, Oisen MA, Branchek TA, Hartig PR: Molecular cloning and characterization of a high affinity dopamine receptor (Dl beta) and its pseudogene. JBiol Chem. 1991, 266: 22427-22435.Google Scholar
- Sedvall G, Farde L: Chemical brain anatomy in schizophrenia. Lancet. 1995, 340: 743-749. 10.1016/S0140-6736(95)91508-7.View ArticleGoogle Scholar
- Davidson M, Harvey PD, Bergman RL, Powchik P, Kaminsky R, Losonczy MF, Davis KL: Effects of the Dl agonist SKF-38393 combined with haloperidol in schizophrenic patients. Arch Gen Psychiatry. 1990, 47: 190-191.View ArticlePubMedGoogle Scholar
- Den Boer JA, van Megen HJ, Fleischhacker WW, Louwerens JW, Slaap BR, Westenberg HG, Burrows GD, Srivastava ON: Differential effects of the Dl-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. Psychopharmacology. 1995, 121: 317-322.View ArticlePubMedGoogle Scholar
- Lidow MS, Elsworth JD, Goldman-Rakic PS: Down-regulation of the Dl and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. J Pharmacol Exp Ther. 1997, 281: 597-603.PubMedGoogle Scholar
- Strange PG: New insights into dopamine receptors in the central nervous system. Neurochem Int. 1993, 22: 223-236. 10.1016/0197-0186(93)90050-F.View ArticlePubMedGoogle Scholar
- Meador-Woodruff JH, Mansour A, Saul J, Watson SJ: Neuroanatomical distribution of dopamine receptor messenger RNAs:. In Niznik HB, ed. Dopamine receptors and transporters. New York, Marcel Dekker,. 1994, 401-415.Google Scholar
- Csemansky JG, Murphy GM, Faustman WO: Limbic/mesolimbic connections and the pathogenesis of schizophrenia. Biol Psychiatry. 1991, 30: 383-400. 10.1016/0006-3223(91)90295-W.View ArticleGoogle Scholar
- Farde L, Hall H, Ehrin E, Sedvall G: Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science. 1986, 231: 258-261.View ArticlePubMedGoogle Scholar
- Shenkman L, Rabey JM, Gilad GM: Cholinergic muscarinic binding by rat lymphocytes: effect of antagonist treatment, strain and aging. Brain Res. 1986, 380: 303-308. 10.1016/0006-8993(86)90226-X.View ArticlePubMedGoogle Scholar
- Nagai Y, Ueno S, Saeki Y, Soga F, Hirano M, Yanagihara T: Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology. 1996, 46: 791-795.View ArticlePubMedGoogle Scholar
- Schmauss C, Haroutunian V, Davis KL, Davidson M: Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc Nati Acad Sci USA. 1993, 90: 8942-8946.View ArticleGoogle Scholar
- Baron JC, Martinet JL, Cambon H, Boulenger JP, Poirier MF, Caillard V, Blin J, Huret JD, Loc'h C, Maziere B: Striatal dopamine receptor occupancy during and following neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology. 1989, 99(4): 463-472.View ArticleGoogle Scholar
- Crow TJ: The two-syndrome concept: origins and current status. Schizophr Bull. 1985, 11: 471-486.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/2/3/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.